Alvotech Reports the Initiation of Confirmatory Trial of AVT16 (Biosimilar, Entyvio)
Shots:
- Alvotech has begun the confirmatory trial of AVT16, biosimilar version of Entyvio (vedolizumab), that targets alpha-4-beta-7 protein for treating Ulcerative Colitis and Crohn’s disease
- The P-III (AVT16-GL-C01) trial is a double-blind, two-arm study comparing the efficacy, safety & immunogenicity of AVT16 vs Entyvio in patients of age 18-80yrs. with moderate to severe active Ulcerative Colitis
- Alvotech's biosimilars portfolio targets autoimmune, eye, bone, respiratory diseases, and cancer. The company plans marketing applications for 3 biosimilars in 2024, with AVT16 among 6 earlier-stage programs
Ref: Alvotech | Image: Alvotech
Related News:- EMA Accepted the Marketing Application of Alvotech’s AVT06 a Biosimilar of Eylea (aflibercept)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
alvotech
avt16
biosimilar
entyvio (vedolizumab)
alpha-4-beta-7 protein
ulcerative colitis
crohn’s disease
p-iii (avt16-gl-c01) trial
double-blind study
immunogenicity
patients
biosimilars portfolio
autoimmune diseases
eye
bone
respiratory diseases
cancer
marketing applications
earlier-stage programs
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
